Michèle Ollier

Michèle is a co-founder and Venture Partner at Medicxi. Prior to Medicxi, Michèle was a Partner at Index Ventures for 10 years, having joined in 2006. Michèle currently serves on the board of a number of portfolio companies, including Kaerus Biosciences, Aldena Therapeutics, Villaris Therapeutics and Nira Biosciences. Investments led by Michèle include OncoEthix (sold to Merck Pharmaceuticals), Minerva Neurosciences (NASDAQ: NERV), Pearl River Bio and Palladio Biosciences (both acquired by Centessa Pharmaceuticals) and Aegerion (NASDAQ: AEGR).

Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/ Gencell/ Aventis International and Serono International. 

She currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN) and sits on the investment committee of the accelerator and technology transfer companies of Paris-Saclay and France-Nord. 

Michèle completed her medical studies in France at Paris Ouest University.